IL1R2

Across TCGA pan-cancer cohorts, IL1R2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated IL1R2 data layer compared with 23 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher IL1R2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IL1R2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

OV, UCEC, and PRAD are the cancer types where IL1R2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.308	0.691	.033	18	view →
UCEC	DFS	Median	All	1.000	0.630	.026	8	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
BLCA	OS	Median	III,IV	0.201	0.579	.042	3	view →
SKCM	DFS	Median	III,IV	0.121	0.654	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

IL1R2–OV (OS)

Open the OV breakdown →